LH · News · 20260804N
Product Launch and Transition
LABCORP HOLDINGS INC. · 2026-08-04 · Importance 38 · Surprise 60 · In source text
Labcorp launched nationwide the Roche VENTANA PTEN (SP218) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma. The assay identifies PTEN protein loss in tumors, helping clinicians determine which patients may be eligible for combination treatment with AstraZeneca’s TRUQAP (capivasertib), abiraterone acetate, and prednisone. The launch expands Labcorp’s precision-oncology testing offering and supports biomarker-driven treatment decisions in the U.S. prostate-cancer market.
Key facts
- Labcorp announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Labcorp announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay. |